In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
Katsuhisa UchidaH Yamaguchi

Abstract

The in vitro activity of luliconazole (NND-502), a novel imidazole antifungal agent, against dermatophytes and several other groups of medically important fungi including the rare causative agents of dermatomycoses, was studied. The luliconazole susceptibility tests were performed with a total of 58 fungal strains of 23 species of fungi grouped into dermatophytes, dematiaceous fungi, hyaline hyphomycetes, yeastlike fungi, and zygomycetes using a broth microdilution method with RPMI 1640 medium. The minimum inhibitory concentration (MIC) values for luliconazole were compared with those of three reference drugs, lanoconazole (LCZ), bifonazole (BFZ), and terbinafine (TBF), all of which have been popular for the topical treatment of dermatophytosis, cutaneous candidiasis, and other superficial fungal infections in Japan. Luliconazole inhibited growth of all filamentous fungi except zygomycetes at low concentrations (MIC, < or =0.004-0.125 microg/ml), with dermatophytes being most susceptible (MIC, < or =0.004-0.008 microg/ml). The susceptibility of these filamentous fungi to luliconazole was almost equal to that to LCZ, and surpassed TBF and BFZ, although to a lesser extent; yeastlike fungi were also susceptible to luliconazole (MI...Continue Reading

Citations

Dec 31, 2008·Medical Mycology·Hiroyasu KogaRyoji Tsuboi
Jan 30, 2014·Anais Brasileiros De Dermatologia·Maria Fernanda Reis Gavazzoni DiasDavid Rubem Azulay
Nov 30, 2011·Medical Mycology Journal·Shigeharu InouyeShigeru Abe
Nov 13, 2015·Expert Review of Anti-infective Therapy·Michael H Gold, Jason T Olin
Apr 27, 2012·Expert Opinion on Pharmacotherapy·Aditya K Gupta, Fiona C Simpson
Sep 28, 2013·Expert Opinion on Investigational Drugs·Aditya K Gupta, Fiona C Simpson
Dec 8, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Mustafa M A Elsayed
Mar 5, 2016·Medical Mycology Journal·Tsuyoshi ShimamuraNobuo Kubota
Jul 11, 2006·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Hiroyasu KogaHideyo Yamaguchi
Dec 3, 2016·Medical Mycology Journal·Tsuyoshi ShimamuraKazutoshi Shibuya
Apr 9, 2014·Antimicrobial Agents and Chemotherapy·Nathan P WiederholdAmir Tavakkol
Nov 7, 2006·Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology·Hiroyasu KogaRyoji Tsuboi
Oct 22, 2019·Journal of Liposome Research·Manjot KaurSubheet Kumar Jain
Sep 17, 2015·Current Opinion in Infectious Diseases·Nathan P Wiederhold, Thomas F Patterson
Nov 2, 2020·Molecular Biology Reports·Maral GharaghaniAli Zarei Mahmoudabadi
Aug 6, 2021·Journal of Basic Microbiology·Saraswathi NagarajShoba Narayan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Related Papers

Journal of Pharmaceutical and Biomedical Analysis
Monika Bakshi, Saranjit Singh
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
Hiroyasu KogaH Yamaguchi
International Journal of Antimicrobial Agents
Katsuhisa UchidaH Yamaguchi
© 2021 Meta ULC. All rights reserved